Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus IBUPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus IBUPROFEN SODIUM.
CHILDREN'S MOTRIN vs IBUPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Category C
Category D/X
NSAID
NSAID